Literature DB >> 2474446

Cell surface antigen CD5 is a marker for activated human B cells.

C Werner-Favre1, T L Vischer, D Wohlwend, R H Zubler.   

Abstract

A minor subset of B cells which in vivo express the surface antigen CD5, has attracted much attention because of its involvement in autoimmune responses. On the basis of observations showing self-renewal capacity of such cells in mice and also the absence of a substantial change of CD5 phenotype during B cell activation in vitro, the CD5+ B cells are now generally considered to represent a separate cell lineage. In the present study, CD5- B cells were isolated by cell sorter and then stimulated in vitro with mutagenized EL4 thymoma cells in the presence of T cell supernatant. About 70% of the B cells were CD5+ after 3 days. Thus, the CD5 antigen behaves as a B cell activation marker. In our system we found that the frequency of rheumatoid factor-producing B cells was on average three times higher in CD5+ than in CD5- B cells isolated ex vivo from human peripheral blood. Most likely this reflects frequent activation of such autoreactive B cells in vivo.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2474446     DOI: 10.1002/eji.1830190709

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  19 in total

1.  Identification and analysis of a novel human surface CD5- B lymphocyte subset producing natural antibodies.

Authors:  M T Kasaian; H Ikematsu; P Casali
Journal:  J Immunol       Date:  1992-05-01       Impact factor: 5.422

2.  Frequencies of HIV-reactive B cells in seropositive and seronegative individuals.

Authors:  R H Zubler; L H Perrin; A Doucet; X Zhang; Y P Huang; P A Miescher
Journal:  Clin Exp Immunol       Date:  1992-01       Impact factor: 4.330

3.  Decreased expression of complement receptor type 2 (CR2) on neoplastic B cells of chronic lymphocytic leukaemia.

Authors:  J A Tooze; D H Bevan
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

4.  CD5 expression on B cells may be an activation marker for secretion of anti-myelin antibodies in patients with polyneuropathy associated with monoclonal gammopathy.

Authors:  C Ekerfelt; J Ernerudh; G Solders; M Vrethem
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

5.  Synthesis of anti-acetylcholine receptor antibodies by CD5- B cells from peripheral blood of myasthenia gravis patients.

Authors:  F Heidenreich; T Jovin
Journal:  J Neurol       Date:  1996-01       Impact factor: 4.849

6.  Detection of lymphocyte subsets using three-color/single-laser flow cytometry and the fluorescent dye peridinin chlorophyll-alpha protein.

Authors:  B Afar; J Merrill; E A Clark
Journal:  J Clin Immunol       Date:  1991-09       Impact factor: 8.317

7.  Complement activation by malignant B cells from patients with chronic lymphocytic leukaemia (CLL).

Authors:  H V Marquart; K Grønbaek; B E Christensen; S E Svehag; R G Leslie
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

8.  Human rheumatoid B-1a (CD5+ B) cells make somatically hypermutated high affinity IgM rheumatoid factors.

Authors:  L Mantovani; R L Wilder; P Casali
Journal:  J Immunol       Date:  1993-07-01       Impact factor: 5.422

9.  Expression of CD5 and CD72 on T and B cell subsets in rheumatoid arthritis and Sjögren's syndrome.

Authors:  C Jamin; A Lamour; Y L Pennec; M Hirn; P Le Goff; P Youinou
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

10.  IL-4 down-regulates the surface expression of CD5 on B cells and inhibits spontaneous immunoglobulin and IgM-rheumatoid factor production in patients with rheumatoid arthritis.

Authors:  T Hidaka; A Kitani; M Hara; M Harigai; K Suzuki; Y Kawaguchi; T Ishizuka; M Kawagoe; H Nakamura
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.